Molecular Partners
Chairman of the Board Dr. Patrick Amstutz, Chief Executive Officer Dr. Michael Stumpp, Chief Operating Officer Andreas Emmenegger, Chief Financial Officer Dr. Nicolas Leupin, Chief Medical Officer | |
Total assets | CHF 145.6 million (Mar. 31, 2021)[1] |
---|---|
Number of employees | 152 FTE (Mar. 31, 2021) [1] |
Website | www.molecularpartners.com |
Molecular Partners AG is a clinical-stage
History
Researchers at the
Molecular Partners became a publicly traded company in November 2014, when it was listed on the SIX Swiss Exchange (ticker MOLN).[4][5]
Since July 2021, the company is also listed on the Nasdaq in the US under the ticker symbol MOLN.[6]
DARPins
DARPins are
The simplest format of a DARPin is the mono-DARPin, consisting of one DARPin domain with specificity for one target. The
Currently, Molecular Partners has two DARPin molecules in clinical development and a broad pipeline of molecules in preclinical development.[1]
Areas of Focus
Molecular Partners is currently focusing its DARPin platform on the fields of oncology, immuno-oncology, ophthalmology, and infectious diseases.[1][8]
Partnerships/Business Development
Molecular Partners has negotiated three agreements with Allergan to develop therapies for ophthalmology (including abicipar), one in 2011[9] and two in 2012.[10] In 2011, the company licensed its lead asset back then, abicipar, to Allergan.[9] In 2012, Molecular Partners and Allergan expanded their relationship by signing two separate new agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.[10]
Since the company's inception in 2004, Molecular Partners licensed additional DARPin candidates to other leading international pharmaceutical companies, such as Amgen, Roche or Janssen.[11]
In October 2020, as part of a joint venture to develop therapeutic drugs to combat COVID-19,[12] the Swiss pharmaceutical giant Novartis bought 6% of all shares outstanding in Molecular Partners at 23CHF a share.[13]
References
- ^ a b c d e Molecular Partners Interim Management Statement Q1 2021.
- ^ "Molecular Partners raised CHF 18.5m in Series A Equity Financing Round". Lenz & Staehelin. August 2007. Retrieved 21 October 2021.
- ^ PMID 25562645.
- ^ Förster, Jan-Henrik (November 5, 2014). "Bloomberg". Bloomberg. Retrieved September 29, 2016.
- ^ "2014 Annual Report" (PDF). Molecular Partners. March 2015. Retrieved September 29, 2016.
- ^ Company PR (June 15, 2021). "Press Release on US Listing". Molecular Partners Pipeline.
- S2CID 1191035.
- ^ "Annual Report 2021". Molecular Partners Financial Filings.
- ^ a b Allergan Licenses Molecular Partners’ Phase II Eye Disease Protein Therapeutic for $45M". Genetic Engineering and Biotechnology News. May 4, 2011.
- ^ a b "Molecular Partners Gets $62.5M as Allergan Repeats on Darpins". Bioworld. August 21, 2012.
- ^ "Molecular Partners and Amgen Announce Strategic Collaboration in Immuno-oncology". Company PR.
- ^ Pfister, Franziska (2 October 2021). "Der Endspurt um die Pille gegen Covid-19 läuft". NZZ am Sonntag (in German). Retrieved 21 October 2021.
- ^ Global Legal Chronicle Molecular Partners Option and License Agreement with Novartis (30 October 2020)